PRMT5 and neoplasm: Mechanistically, in diseases harboring AS factor mutations (such as MDS and chronic myelomonocytic leukemia), tumor cells become dependent on PRMT5 to maintain a “barely stable” splicing system; thus, PRMT5 inhibition induces synthetic lethality, selectively triggering tumor cell death [343,344].